Worried about energy, memory, or unexplained tingling in your hands and feet? B12 deficiency silently damages nerves and red blood cells long before obvious symptoms emerge. This is particularly relevant if you follow a plant-based diet without supplementation, take long-term medications like metformin or proton pump inhibitors, or have a family history of pernicious anemia — a common autoimmune condition in older Swedish adults that blocks B12 absorption.

Standard Swedish vårdcentralen testing includes B12, but the results are often interpreted narrowly. Borderline-low levels (150–250 pmol/L) with neurological symptoms or elevated homocysteine warrant deeper investigation with active B12 or methylmalonic acid (MMA) testing, which are more sensitive to functional B12 deficiency.

• Detects silent deficiency early. B12 deficiency can progress for years without obvious symptoms, causing irreversible nerve damage. Testing identifies it before neurological injury occurs.

• Flags pernicious anemia and absorption problems. Low B12 signals either dietary insufficiency, autoimmune attack on intrinsic factor (pernicious anemia), or medication-induced malabsorption — each requires different intervention.

• Clarifies neurological symptoms. Paresthesias, cognitive fog, memory problems, or gait changes can be reversed if B12 deficiency is caught and corrected early, but delayed diagnosis leads to permanent spinal cord damage.

• Guides medication use. If you take metformin, proton pump inhibitors (omeprazole, pantoprazole), H2-blockers (ranitidine), or have undergone gastric surgery, B12 monitoring helps prevent deficiency before it becomes symptomatic.

• Contextualizes anemia and high MCV. When hemoglobin is low or mean corpuscular volume is elevated, B12 testing identifies megaloblastic anemia caused by impaired DNA synthesis, distinguishing it from iron deficiency or other causes.

• Catches false-normal elevations. Rarely, elevated B12 without supplementation signals hematologic malignancy or liver disease and warrants investigation; functional B12 tests (holotranscobalamin, MMA) provide nuance.

The essential cofactor for two critical reactions. B12 (cobalamin) is a water-soluble vitamin that exists in the body as methylcobalamin and adenosylcobalamin — active forms that catalyze methylation reactions and mitochondrial energy metabolism. The two key roles are: (1) donating a methyl group to convert homocysteine back to methionine, which is necessary for DNA synthesis, myelin formation, and 1-carbon metabolism; and (2) supporting succinyl-CoA mutase in mitochondrial energy metabolism and odd-chain fatty acid breakdown.

How absorption works and why it fails. Dietary B12 (from animal products, some fortified foods, and some fermented foods) binds to intrinsic factor — a glycoprotein produced by stomach parietal cells. The B12–intrinsic-factor complex is then absorbed in the terminal ileum. Pernicious anemia occurs when autoimmune attack destroys parietal cells or intrinsic factor itself, blocking this absorption entirely. Atrophic gastritis (common with age, especially in older Swedes with a history of Helicobacter infection) also destroys parietal cells. Medications that suppress stomach acid — proton pump inhibitors (omeprazole, pantoprazole, esomeprazole) and H2-blockers — reduce the low pH necessary to release B12 from food proteins, preventing absorption. Metformin, while not directly blocking absorption, may reduce B12 transporters in the terminal ileum. Crohn's disease and post-gastric-surgery patients lose absorptive surface. Strict vegans without supplementation deplete stores over years.

The consequence of deficiency: megaloblastic anemia and neurological damage. Without adequate B12 for DNA synthesis, red blood cells and white blood cells develop abnormally, producing fewer but larger cells (megaloblasts). This causes megaloblastic anemia with elevated MCV, reticulocytopenia (paradoxically low reticulocyte response), and pancytopenia in severe cases. Neurologically, B12 deficiency causes demyelination — myelin sheath damage in peripheral nerves and spinal cord. Early symptoms include paresthesias (tingling, numbness in feet and hands), diminished vibratory and proprioceptive sensation, ataxia, and cognitive changes (memory loss, depression, psychosis in severe cases). Subacute combined degeneration (SCD) of the spinal cord — irreversible spinal cord damage — develops if deficiency persists untreated.

• Prevents irreversible neurological damage. Unlike anemia, which resolves once B12 is restored, neurological damage from prolonged deficiency (subacute combined degeneration of the spinal cord) is permanent. Early detection is the only window to prevent disability.

• Identifies hidden deficiency in at-risk groups. Total serum B12 can be misleadingly "normal" in functional deficiency, especially in patients with early pernicious anemia or long-term metformin use. Pairing B12 with homocysteine and MCV reveals biochemical B12 depletion even when total B12 appears borderline.

• Enables early intervention before symptoms emerge. A single intramuscular injection of hydroxocobalamin bypasses absorption problems entirely — but only if deficiency is detected before permanent nerve damage occurs. Once SCD develops, reversal is incomplete.

• Contextualizes otherwise unexplained anemia and cognitive decline. B12 deficiency frequently coexists with other nutritional deficiencies (folate, iron) and metabolic dysfunction, amplifying risk. Isolating B12 as a driver of elevated homocysteine and MCV sharpens diagnosis and guides treatment efficacy.

• Standard Swedish reference (vårdcentralen): >150 pmol/L is typically considered "normal" by most Swedish labs; however, this range is based on the lower percentile of the population, not on clinical thresholds for neurological or hematologic safety.

• Loovi optimal (longevity): >300 pmol/L. Above this threshold, the risk of functional deficiency and neurological symptoms is substantially lower. Patients with borderline B12 (150–250 pmol/L) should be evaluated more rigorously, especially if they have neurological symptoms, elevated homocysteine (>12 µmol/L), elevated MCV (>100 fL), or are on medications that impair absorption.

• Functional deficiency zone (borderline-low): 150–250 pmol/L. In this range, total serum B12 may appear acceptable, but functional deficiency is common. If the patient has symptoms (paresthesias, cognitive changes), elevated homocysteine, or elevated MCV, active B12 (holotranscobalamin) or MMA testing is warranted to assess true B12 status.

• Elevated B12 without supplementation: >700 pmol/L. Rarely, unsupplemented elevated B12 signals hematologic malignancy (myelodysplasia, chronic myeloid leukemia, polycythemia vera) or liver disease, where hepatocytes release stored B12 into circulation. This warrants hematologic and hepatic evaluation.

The boundary between "normal" and "optimal" is critical: a Swedish vårdcentralen may report B12 of 200 pmol/L as "normal" and not intervene, yet this level poses significant neurological risk, especially in older adults with atrophic gastritis or on metformin.

Low (<150 pmol/L). Clear B12 deficiency. The cause must be identified: if dietary (vegan without supplements), supplementation is straightforward; if pernicious anemia (antibodies to intrinsic factor or parietal cells), lifelong intramuscular B12 injections are required; if medication-induced (metformin, PPI, H2-blocker), dose reduction or deprescribing may reverse it; if post-gastric surgery or Crohn's disease, parenteral B12 may be necessary. Neurological symptoms and elevated homocysteine or MMA will be present. Hemoglobin and MCV should be checked for megaloblastic anemia.

Borderline-low (150–250 pmol/L) with neurological symptoms or elevated homocysteine. Functional B12 deficiency is likely. Active B12 (holotranscobalamin) or methylmalonic acid (MMA) should be measured. If active B12 is low or MMA is elevated, the patient has functional deficiency despite a borderline total B12 and warrants supplementation or investigation for pernicious anemia. This pattern is common in older Swedish adults with early atrophic gastritis or on long-term metformin.

Optimal (>300 pmol/L). B12 status is adequate. Neurological symptoms and elevated homocysteine are unlikely to be B12-driven (consider other causes: folate deficiency, thyroid dysfunction, methylenetetrahydrofolate reductase (MTHFR) mutations, or primary neurologic disease). Continue routine intake or maintain supplementation if on a plant-based diet.

Elevated (>700 pmol/L) without supplementation or injection. Rare. Warrants hematologic and hepatic assessment to rule out myelodysplasia, chronic myeloid leukemia, or cirrhosis. If the patient is not on supplementation, this finding should trigger further investigation.

Factors that influence vitamin B12 levels: pregnancy (increased demand), recent viral or bacterial infection (acute phase; B12 can be falsely elevated), oral contraceptives and hormone replacement (may lower B12 slightly), metformin and other medications affecting absorption, intense exercise (short-term, generally not clinically significant), menstrual cycle (minimal effect), blood transfusion (can raise B12 artificially), and chemotherapy (can deplete stores).

• Dietary insufficiency. Vegans and strict vegetarians who do not consume fortified foods or supplements gradually deplete B12 stores over years. B12 is found almost exclusively in animal products; plant sources like nutritional yeast and fortified non-dairy milks are unreliable unless their B12 content is verified. Elderly people with poor diet may also be at risk.

• Pernicious anemia (autoimmune; very common in Sweden). Autoantibodies against intrinsic factor or gastric parietal cells prevent B12 absorption. This is particularly common in older Swedes, especially those with a family history of thyroid disease or other autoimmune conditions. Diagnosis is confirmed by intrinsic-factor antibody testing. Lifelong intramuscular B12 supplementation is required.

• Atrophic gastritis and Helicobacter infection. Chronic inflammation of the stomach mucosa (often due to past or current Helicobacter pylori infection, which is prevalent in older Swedes) destroys parietal cells, reducing intrinsic factor and stomach acid. This prevents both protein digestion and B12 release from food. Eradication of H. pylori can arrest but not fully restore parietal-cell function.

• Medication-induced malabsorption. Proton pump inhibitors (omeprazole, pantoprazole, esomeprazole), H2-receptor antagonists (famotidine, ranitidine in older patients), and metformin all impair B12 absorption. Long-term use (years) gradually depletes stores. Dose reduction or deprescribing — if clinically safe — can reverse deficiency. Patients on these drugs long-term should be monitored.

• Post-surgical and malabsorptive conditions. Gastric bypass surgery removes the fundus (parietal-cell-rich region) and shortens the terminal ileum (main B12 absorption site). Crohn's disease, celiac disease (if not well-controlled), and cystic fibrosis all reduce absorptive surface or increase B12 losses. These patients require lifelong B12 supplementation (oral high-dose or intramuscular).

• Dietary optimization (for insufficiency only). If deficiency is dietary, increase consumption of B12-rich foods: meat, fish, eggs, dairy products, and shellfish. Vegans should rely on fortified non-dairy milks and nutritional yeast with verified B12 content, or daily oral cyanocobalamin supplements (25–100 µg daily or 2000 µg twice weekly). Oral supplementation works even in malabsorption because high doses bypass the intrinsic-factor-dependent pathway through passive diffusion.

• Medication review and deprescribing. If metformin, a proton pump inhibitor, or an H2-blocker is the driver, deprescribing (where clinically safe) or dose reduction may restore B12 absorption. For example, switching from daily omeprazole to on-demand use or from metformin to an alternative diabetes medication (if glycemic control permits) can halt B12 depletion and allow stores to recover. This requires discussion with the clinician managing the underlying condition.

• Parenteral supplementation (for pernicious anemia and severe malabsorption). Intramuscular hydroxocobalamin (typically 1000 µg) bypasses absorption problems entirely. Pernicious anemia requires lifelong therapy, usually given monthly or every 3 months. Post-gastric-surgery patients and those with Crohn's also require ongoing parenteral B12 to prevent relapse. Oral high-dose supplements (2000 µg daily) can be tried first, but many patients need injections for reliable repletion.

• Monitoring homocysteine and MCV as secondary markers. Even after B12 supplementation begins, normalization of elevated homocysteine and MCV takes weeks to months. Homocysteine is a more sensitive marker of B12 effect than serum B12 itself, and MCV reflects RBC recovery from megaloblastic changes. If homocysteine remains elevated despite apparently adequate B12, consider folate deficiency (which often coexists) or other causes of hyperhomocysteinemia (see folate and homocysteine biomarker pages).

The optimal intervention depends on the root cause: dietary insufficiency, medication-induced deficiency, pernicious anemia, or post-surgical malabsorption each require different strategies. A Loovi longevity doctor integrates B12 status with folate, homocysteine, and MCV to design a personalized plan.

B12 is never a lone marker. It works as part of 1-carbon metabolism alongside folate, methionine, and homocysteine. Testing B12 alone misses folate deficiency (which causes identical megaloblastic anemia) and fails to explain why homocysteine is elevated despite borderline-normal B12. Pernicious anemia can cause intrinsic-factor and parietal-cell antibodies that also attack the stomach's H+-ATPase pump, reducing stomach acid — this indirectly impairs iron and calcium absorption too, making ferritin and vitamin D relevant context. MCV (mean corpuscular volume) is the red-cell size marker that clinches whether anemia is megaloblastic (B12 or folate-driven) or microcytic (iron-driven); without it, you're interpreting hemoglobin in a vacuum. And if symptoms are neurological, TSH and free thyroxine must be checked to rule out thyroid dysfunction, which causes identical cognitive and mood symptoms.

Loovi's 120+ biomarker annual tracking captures B12, folate, homocysteine, hemoglobin, MCV, ferritin, and thyroid function in one panel. This integrated view reveals the real drivers of anemia and neurological risk, guides personalized supplementation, and prevents the single-marker misinterpretation that leaves patients symptomatic despite a "normal" B12 result.